Last update 18 Dec 2024
Zibotentan/Dapagliflozin
Last update 18 Dec 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism ETA antagonists(Endothelin receptor type A antagonists), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC19H16N6O4S |
InChIKeyFJHHZXWJVIEFGJ-UHFFFAOYSA-N |
CAS Registry186497-07-4 |
View All Structures (2)
Related
4
Clinical Trials associated with Zibotentan/Dapagliflozin一项在慢性肾脏病和高蛋白尿受试者中评价Zibotentan/达格列净与达格列净单药治疗相比的有效性、安全性和耐受性的 III期、随机、多中心、双盲研究
[Translation] A Phase III, randomized, multicenter, double-blind study to evaluate the efficacy, safety, and tolerability of Zibotentan/dapagliflozin compared with dapagliflozin monotherapy in subjects with chronic kidney disease and hyperalbuminuria
A Multicentre, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Combination Compared to Zibotentan Monotherapy, Zibotentan/Dapagliflozin and Zibotentan Monotherapy Compared to Placebo in Participants With Cirrhosis
A Study to Assess the Effects of the Endothelin Receptor Antagonist Zibotentan and the SGLT2 Inhibitor Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria: a Randomized Double Blind Cross-Over Trial
100 Clinical Results associated with Zibotentan/Dapagliflozin
Login to view more data
100 Translational Medicine associated with Zibotentan/Dapagliflozin
Login to view more data
100 Patents (Medical) associated with Zibotentan/Dapagliflozin
Login to view more data
100 Deals associated with Zibotentan/Dapagliflozin
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic Kidney Diseases | Phase 3 | US | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | CN | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | JP | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | AR | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | AU | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | AT | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | BR | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | BG | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | CA | 07 Nov 2023 | |
| Chronic Kidney Diseases | Phase 3 | DK | 07 Nov 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free